Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Practice bulletins > #140 Management of Abnormal Cervical Cancer Screening Test Results and Cervical Cancer Precursors > Flashcards

#140 Management of Abnormal Cervical Cancer Screening Test Results and Cervical Cancer Precursors Flashcards

1
Q

Is HPV infection more likely to be transient or permanent?

A

Transient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Persistence of HPV for how long strongly predicts subsequent risk of CIN3?

A

1-2 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which HPV genotype has the highest carcinogenic potential?

A

HPV 16

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What percentage of cervical cancers are caused by HPV 16 worldwide?

A

Approximately 55-60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the second most carcinogenic HPV genotype?

A

HPV 18

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What percentage of cervical cancers are caused by HPV 18?

A

10-15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are risk factors known to increase likelihood of HPV persistence?

A

Cigarette smoking, compromised immune system, HIV infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

At what age range is HPV infection most common?

A

Teenagers and early 20s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the lifetime risk of HPV infection?

A

80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

In what time frame do young healthy women typically clear HPV infection?

A

Average of 8 months.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

In the young population, does clearing of HPV also lead to spontaneous resolution of cervical neoplasia?

A

Most of the time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is CIN1?

A

Manifestation of acute HPV infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How is CIN1 managed?

A

Usually can be managed expectantly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the typical time course of progression from CIN 3 to invasive cancer?

A

Between 8.1 to 12.6 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What %tage of women with LSIL will have CIN2-3?

A

28%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Is HPV testing more or less sensitive to cytology testing?

A

More sensitive. Less specific.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What increases the sensitivity of colposcopy?

A

Additional biopsies. Increased detection with random biopsies in addition to directed biopsies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What techniques can be used for endocervical sampling during colposcopy?

A

Sharp curette, vigorous endocervical brushing, or both. Curette followed by brush.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

When should endocervical sampling be performed at time of colposcopy?

A
  • Women with ASCUS or LSIL with no lesion on colposcopy, unsatisfactory colposcopy, previous excision or ablation of transformation zone
  • Women with ASC-H, HSIL, AGC, or AIS ECC should be considered part of initial colpo exam, unless excision is planned
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How frequent do you perform cervical cytology screening?

A

q3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How frequently do you perform cervical cotesting?

A

q5 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

How long after treatment do women with hx CIN2+ have increased risk of recurrence?

A

Up to 20 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

At what age do you start cervical cancer screening for general population?

A

21 years old

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What does LSIL represent?

A

Productive HPV infection, majority transiet and unlikely to progress to cancer. CIN1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What does HSIL represent?

A

Precancerous lesions. CIN 2 and CIN 3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How do you manage an unsatisfactory cervical cytology test result and no, unknown, or negative HPV?

A

Repeat cytology in 2-4 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

How do you manage unsatisfactory cervical cytology with positive HPV co-test (>30yo)?

A

Repeat cytology in 2-4mo or colposcopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

How do you manage two consecutive unsatisfactory cervical cytology test results?

A

Colposcopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

How do you manage negative cytology test results with absent or insufficient endocervical-transformation zone component (age 21-29)?

A

Routine screening recommended. HPV testing is unacceptable.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

How do you manage negative cytology test results with absent or insufficient endocervical-transformation zone component and no or unknown HPV testing (age >30)?

A

HPV testing is preferred. Repeat cytology in 3 years if HPV testing not performed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

How do you manage >30yo NILM, HPV neg with absent or insufficient endocervical-transformation zone?

A

Return to routine screening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

How do you manage >30yo NILM, HPV+ with absent or insufficient endocervical-transformation zone?

A

Repeat cotesting in 1 year is acceptable. Genotyping is acceptable, if HPV 16 or 18, colposcopy is recommended. If 16, 18 negative, repeat cotesting in 12 mo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Do women with insufficient endocervical-transformation zones sampling on pap have an increased risk of having CIN2+?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

How do you manage a 30+ year old with cytology negative, HPV positive pap smear?

A

Option 1: HPV genotyping, HR HPV -> colposcopy

Option 2: cotesting 1 year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Next step in pap management:

30+ year old w/ NILM, HPV+ pap, repeat cotesting in 1 year is NILM, HPV neg

A

Repeat cotesting in 3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What pap result on cotesting 12 months after 30+ yo w/ NILM, HPV+ pap would lead you to do colposcopy?

A

HPV+ with any cytology.

ASCUS or greater

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What is the % chance of CIN2+ with normal cytology and single HPV positive result?

A

2.2 - 6.1% risks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What is the risk of CIN3+ over the next several years in woman with HPV16?

A

Approaches 10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What is next step in management: 25+yo ASCUS, HPV negative?

A

Repeat cotesting in 3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What is next step in management: 25yo+ ASCUS, HPV+

A

Colposcopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What is next step in management? 25yo+ ASCUS, HPV+ with negative colposcopy

A

Cotesting at 12 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What is next step in management? 25yo+ ASCUS, HPV+ > negative colpo > HPV+ at 12mo cotesting

A

Repeat colposcopy (colposcopy for anything ASCUS or higher or persistent HPV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What is next step in management? 25yo+ ASCUS, HPV+ > negative colpo > Cotesting ASCUS HPV-

A

Repeat colposcopy (colposcopy for anything ASCUS or higher or persistent HPV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What is the next step in management? 25yo+ with ASCUS and no HPV testing?

A

Repeat cytology at 1 year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What is the next step in management? 25yo+ ASCUS (no HPV testing) > 12mo cytology = ASCUS or higher

A

Colposcopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

What is the next step in management? 65yo+ (for whom you were planning to discontinue screening) w/ ASCUS results?

A

Consider abnormal, repeat testing in 12 months, cotesting preferred

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

What is the next step in management? 25yo+ LSIL, HPV negative?

A

Option 1: cotesting at 1 year (preferred)

Option 2: colposcopy (acceptable)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

What is the next step in management? 25yo+, LSIL, HPV positive

A

Colposcopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

What is the next step in management? 25yo+ LSIL, HPV negative > repeat cotesting (1 yr) LSIL

A

Colposcopy. Colposcopy if repeat cotesting ASCUS or greater or HPV+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

What is the next step in management? 25yo+ LSIL, HPV negative > repeat cotesting (1 yr) NILM, HPV-

A

Repeat cotesting in 3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

What is the next step in management? Postmenopausal LSIL and no HPV testing?

A

Option 1: obtain HPV testing
Option 2: cytology at 6 and 12 months
Option 3: colposcopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What is the next step in management? Age 25-29 LSIL, no HPV testing?

A

Colposcopy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

What percentage of women with LSIL have CIN2+ on colposcopy or will develop CIN2+ within the next 2 years?

A

27.6%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

What percentage of patients with LSIL are HPV positive?

A

77%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

How to manage patients 21-24yo with ASCUS?

A

Option 1: cytology alone at 12 months (preferred)

Option 2: Reflex HPV testing (acceptable)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

What is next step in management? 21-24yo with ASCUS, HPV negative?

A

Repeat cytology in 3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

What is the risk of cervical cancer in the 21-24yo age group?

A

1.4/100,000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

What is the initial approach for woman 25+yo with ASC-H pap?

A

Colposcopy. Reflex HPV testing NOT recommended

59
Q

What is the 5 year invasive cancer risk for a patient with HPV negative ASC-H pap?

A

2%

60
Q

What is the initial management of 25yo+ with HSIL pap smear?

A

Option 1: Immediate LEEP

Option 2: Colposcopy > diagnostic LEEP if inadequate

61
Q

What percentage of women with HSIL will have CIN2+ on directed biopsy on colposcopy?

A

60%

62
Q

What percentage of women with HSIL will have cervical cancer on colposcopy?

A

2%

63
Q

What is the 5 year cervical cancer risk for patients (30+yo) with HSIL on pap?

A

8%

64
Q

What is the next step in management? HSIL cytology in a woman who has completed child bearing?

A

Immediate excision of the transformation zone. “see and treat” vs colpo with endocervical assessment

65
Q

What is the 5-year risk for CIN3+ for woman with HSIL, HPV neg pap?

A

29%

66
Q

What is the 5-year risk for invasive cancer for woman with HSIL, HPV neg pap?

A

7%

67
Q

Is triage with HPV testing recommended for HSIL cytology?

A

No, HPV status does not change recommendation

68
Q

What is the next step in management for 21-24yo with HSIL or ASC-H cytology?

A

Colposcopy recommended. Immediate treatment (see and treat) is unacceptable

69
Q

What is the next step in management for 21-24yo w/ HSIL cytology, colposcopy negative or CIN1?

A

Cytology and colposcopy testing q6 months for up to 24 months. Return to routine if two consecutive negative cytology and colposcopy results Provided that colposcopic exam is adequate and endocervical assessment is negative or CIN1

70
Q

What is the next step in management in 21-24yo w/ persistent HSIL for 24 months without identification of CIN2+ on colposcopy?

A

Diagnostic excisional procedure is recommended

71
Q

What is the next step in management in 21-24yo with persistent HSIL for 1 year with negative colposcopy?

A

biopsy

72
Q

What is the next step in management for 21-24yo w/ HSIL cytology and inadequate colposcopy?

A

Diagnostic excisional procedure

73
Q

What is the next step in management for 21-24yo w/ HSIL cytology and CIN2+ on endocervical sampling?

A

Diagnostic excisional procedure

74
Q

What is initial work up for women with atypical glandular cells on pap cytology?

A

Colposcopy with endocervical sampling. Add endometrial sampling in 35yo and older. (younger if at risk)

75
Q

What is the initial work up for women with adenocarcinoma in situ on pap cytology?

A

Colposcopy with endocervical sampling. Add endometrial sampling if 35yo or older. (younger if at risk)

76
Q

What is the initial work up for woman with atypical endometrial cells on pap cytology?

A

Initial eval limited to endocervical and endometrial sampling preferred. Colposcopy acceptable at time of initial sampling. Colposcopy recommended if no endometrial abnormality identified

77
Q

What is the next step in managment for woman with atypical glandular cells-not otherwise specified on pap with CIN1 or less on colposcopy?

A

Cotesting at 12mo and 24mo is recommended. If both negative, repeat cotesting in 3 years. Colpo if any test abnomormal

78
Q

What is the next step in management for woman with atypical glandular cells - favor neoplasia on pap, if no invasive disease on initial colpo?

A

Diagnostic excisional procedure recommended - CKC for intact margins, endocervical sampling after excision preferred

79
Q

What is the next step n management for woman with endocervical adenocarcinoma in situ cytology result with no invasive disease on initial colpo?

A

Diagnostic excisional procedure recommended - CKC for intact margins, endocervical sampling after excision preferred

80
Q

What is the reporting rate of atypical glandular cells on pap in the US?

A

0.4%

81
Q

Is atypical glandular cells on pap typically a reproducible interpretation?

A

Poorly reproducible

82
Q

What non cancerous lesions often cause an atypical glandular cells result on pap?

A

reactive changes, polyps

83
Q

What concerning etiologies can result with atypical glandular cells on pap?

A

Squamous dysplasia, adenocarcinoma of cervix, endometrium, ovary, or fallopian tube

84
Q

What percentage of women with pap result atypical glandular cells have CIN2+?

A

9-38%

85
Q

What percentage of women with pap result atypical glandular cells have invasive cancer?

A

3-17%

86
Q

Is an atypical glandular cell cytology result more commonly associated with squamous or glandular lesions?

A

Squamous

87
Q

How should an asymptomatic premenopausal woman with endometrial cells found with cervical cytology testing be managed?

A

No further eval for benign endometrial cells, endometrial stromal cells, or histiocytes

88
Q

How should postmenopausal women with endometrial cells on cervical cytology testing be managed?

A

Endometrial assessment regardless of symptoms

89
Q

What are defined as “lesser abnormalities” on pap smears?

A

HPV 16 or HPV 18 positivity, persistent untyped oncogenic HPV, ASC-US, and LSIL

90
Q

What is the next step in management for 25yo+ w/ lesser abnormalities on pap with no lesion or bx confirmed CIN 1 on colpo?

A

Cotesting at 1 year

91
Q

What is the next step in management for 25yo+ w/ lesser abnormality on pap, neg colpo, then cotesting at 1 year neg?

A

Age-appropriate retesting 3 years later (cotesting 30yo+)

92
Q

What is the next step in management for 25yo+ w/ lesser abnormality on pap, CIN1 colpo persistent for 2 years?

A

Follow-up or treatment (ablative or excisional methods [preferred if colpo inadequate, pos ECC, or previously treated])

93
Q

What is next step in management of 25+yo w/ ASC-H or HSIL pap and no lesion or CIN1 on colpo?

A

Option 1: diagnostic excisional procedure

Option 2: Observation with cotesting at 12 and 24 months (as long as colpo adequate and endocervical sampling neg)

94
Q

What are reasons to not identify CIN2+ lesion in women with ASC-H or HSIL cytology?

A

Cytologic abnormality may be caused by a vaginal lesion, presence of occult CIN2+ not identified because of insensitivity of colpo, or over reading of a non-high-grade cytology specimen by the cytologist

95
Q

How can you identify a vaginal lesion? (what solution?)

A

Both 3-5% acetic acid and Lugol solution

96
Q

Should women with ASC-H on pap be managed similar to women with HSIL or LSIL on pap?

A

HSIL

97
Q

Is pap cytology subjective or objective?

A

Subjective

98
Q

Next step in management for woman with HSIL or ASC-H cytology, no lesion or CIN1 colpo, neg cotesting at 12 and 24 mo

A

Age-appropriate retesting 3 years later (cotesting 30yo+)

99
Q

Next step in management for woman with HSIL or ASC-H cytology, no lesion or CIN1 colpo, neg cotesting at 12mo, any LSIL at 24mo

A

Colposcopy

100
Q

Next step in management for woman with HSIL or ASC-H cytology, no lesion or CIN1 colpo, cotesting at 12mo HSIL

A

Diagnostic excisional procedure

101
Q

Next step in management 21-24yo with CIN1 after ASC-US or LSIL pap?

A

Repeat cytology at 12 months

102
Q

Next step in management 21-24yo with CIN1 after ASC-US or LSIL pap, cytology at 12mo ASC-H?

A

Colposcopy

103
Q

Next step in management 21-24yo with CIN1 after ASC-US or LSIL pap, cytology at 12 months NILM?

A

Repeat cytology at 12mo. (return to routine screening after two consecutive negative cytology)

104
Q

Next step in management 21-24yo with CIN1 after ASC-US or LSIL pap, cytology at 12mo NILM, cytology at 24mo ASC-US?

A

Colposcopy. Colpo for ASC-US or worse.

105
Q

Recommended management for women with recurrent CIN2+ (25yo+, non pregnant)?

A

Diagnostic excisional procedure

106
Q

What percentage of CIN3 regresses if left untreated?

A

32%

107
Q

What percentage of CIN3 persisted if left untreated?

A

56%

108
Q

What percentage of CIN3 progressed to CIN3+ if left untreated?

A

14%

109
Q

What percentage of CIN2 regresses if left untreated in adults? In adolescents?

A

43% in adults. Up to 65% in adolescents.

110
Q

What percentage of CIN2 persists if left untreated?

A

35%

111
Q

What percent of CIN2 progresses to CIN3+ if left untreated?

A

22%

112
Q

Next step in management for “young women” with CIN2 on colpo?

A 
Observation preferred (colpo and cytology q6mo for up to 12 months)
Treatment acceptable
113
Q

Next step in management for “young women” with CIN3 on colpo?

A

Treatment recommended

114
Q

How does the ASCCP define “young women” in context of cervical cancer screening/management?

A

Women who, after counseling by their clinicians consider risk to future pregnancies from treating cervical abnormalities to outweigh the risk of cancer during observation of the abnormalities. No specific age threshold.

115
Q

Should CIN3 be treated regardless of age or fertility concerns?

A

Yes, because it is a definite cervical cancer precursor

116
Q

When are ablative treatments appropriate for treatment of cervical abnormalities?

A

When invasive cancer is excluded. CANNOT USE ABLATION IF: endocervical assessment with CIN, inadequate colpo, cytology or colpo results suggest cancer, after prior therapy

117
Q

What is the efficacy of excisional procedures (LEEP, laser conization, CKC) for CIN?

A

90-95%

118
Q

When do most treatment failures occur after cervical excisional procedure for CIN?

A

Within first 2 years after treatment

119
Q

What must be included in cervical excisional procedures for CIN?

A

Entire transformation zone must be encompassed

120
Q

Which cervical abnormalities necessitate careful attention to margins of excision (consider CKC over other options)?

A

Microinvasive cnacer and adenocarcinoma in situ

121
Q

What is the management for women with CIN2, CIN2,3 or CIN3 after excisional procedure?

A

Cotesting at 12 and 24 months

122
Q

What is the next step in management for women with negative cotesting x 2 after excisional procedure for CIN2, CIN2,3 or CIN3?

A

Retesting in 3 years

123
Q

For how long after an excisional procedure for CIN are women at risk for cancer?

A

Cases of cancer have been found as late as 20 years after initial therapy

124
Q

After excisional procedure for CIN, is HPV testing more sensitive and/or specific than cytology?

A

HPV testing is more sensitive, but less specific. May result in earlier diagnosis of persistent or recurrent disease

125
Q

What is the sensitivity of HPV testing to predict treatment failure after excisional procedure for CIN?

A

Averaged 94.4%

126
Q

If CIN2,3 is identified at the margins of an excisional procedure or post-procedure ECC what is the preferred follow up? What is acceptable follow up?

A

cytology and ECC at 4-6 months is preferred. Repeat excision is acceptable and hysterectomy is acceptable if re-excision is not feasible

127
Q

What is the recurrence rate of CIN2+ after standard treatment in HIV+ women?

A

Greater than 50% recurrence rate

128
Q

How does HIV status and use of antiretrovirals affect managment of CIN2+?

A

It does not. Use same management.

129
Q

What is the recommended cervical screening for women who are HIV+?

A

Annual cytology alone

130
Q

What is the management for women with adenocarcinoma in situ on diagnostic excisional procedure?

A

Hysterectomy preferred if completed childbearing
Conservative acceptable if desire future fertility - If margins involved or endocervical with CIN or AIS reexcision preferred; reevaluation at 6mo w/ cotesting and colpo with endocervical sampling

131
Q

Is adenocarcinoma in situ or CIN2,3 associated with skip lesions?

A

AIS

132
Q

What is important for diagnostic excisional procedure for adenocarcinoma in situ?

A

Intact, deep excision with interpretable margins since AIS frequently extends for a considerable distance into the endocervical canal and has skip lesions

133
Q

Do negative margins for diagnostic excisional procedure for adenocarcinoma in situ mean lesion is completely excised?

A

Not necessarily as AIS is multi focal with skip lesions.

134
Q

What is the risk of persistent adenocarcinoma in situ after deep conization with negative margins?

A

Up to 10%

135
Q

If performing hysterectomy for persistent CIN2+, what route is preferred?

A

Vaginal approach is preferred when feasible (balance safety and patient recovery). Only perform after exclude possibility of invasive cancer.

136
Q

What part of colposcopy cannot be performed during pregnancy?

A

endocervical curettage

137
Q

For which pap cytology that you would perform colpo for, can you defer to the 6wk postpartum visit?

A

ASC-US and LSIL (although preferred for LSIL is to perform during pregnancy, postpartum is ‘acceptable’)

138
Q

When would you repeat a colposcopy during pregnancy? At what interval?

A

Acceptable to do colposcopy and cytology in with w/ CIN2, CIN3, CIN2,3 at intervals no more frequent than q12wks. Repeat bx only if appears worse or cytology suggests invasive cancer

139
Q

When is a diagnostic excisional procedure recommended during pregnancy?

A

Suspected invasive disease

140
Q

Does management of LSIL and HPV-positive ASC-US pap during pregnancy change compared to non pregnant women?

A

No

141
Q

Do you treat CIN during pregnancy?

A

No

142
Q

What are risks of diagnostic excisional procedure during pregnancy?

A

Fetal loss, preterm delivery, maternal hemorrhage

143
Q

For women with CIN2 during pregnancy, what is the risk of microinvasive cancer at the postpartum visit?

A

Negligible

144
Q

For women with CIN3 during pregnancy, what is the risk of microinvasive cancer at the postpartum visit?

A

Substantially less than 10%, deeply invasive types of cancer are rare

Practice bulletins (83 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions